As More than 65 industry players across the world are presently engaged in evaluating the clinical applications of over 180 cannabinoid-derivatives that target the human endocannabinoid signalling sys

 

Over time, extensive R&D on the potential health benefits of cannabis, have enabled medical researchers to identify a number of pharmacologically active ingredients that offer clinical benefit, minus the addictive properties of the crude substance. Currently, several stakeholders in the pharmaceutical industry are actively engaged in the efforts to develop leads based on natural and synthetic derivatives of cannabinoids.

 

• A detailed assessment of the current market landscape of endocannabinoid system targeted therapeutics, providing information on phase of development (clinical, preclinical, and discovery stage) of lead candidates, target therapeutic area (s), route of administration (oral, topical, sublingual, oromucosal, inhalation and others), dosing frequency (once daily, twice daily, thrice daily and others) and target receptor (CB1, CB2, TRPV-1 and others). Additionally, the chapter includes information on drug developer(s), including information on year of establishment, company size, and location of headquarters.
• Elaborate profiles of prominent endocannabinoid system targeted therapeutics developers that are engaged in the development of at least four development programs. Each profile features a brief overview of the company, its financial information (if available), product portfolio and an informed future outlook.

An in-depth analysis of nearly 600 grants that have been awarded to research institutes engaged in endocannabinoid system targeted projects, in the period between 2016 and 2020 (till January), including analysis based on important parameters, such as year of grant award, amount awarded, administration institute centre, funding institute centre, support period, type of grant application, purpose of grant award, grant mechanism, responsible study section, prominent program officers, and type of recipient organizations

 

To order this 250+ page report, which features 140+ figures and 170+ tables, please visit https://www.rootsanalysis.com/reports/view_document/endocannabinoid-therapeutics/316.html

 

The over USD 5 billion (by 2030) financial opportunity within the endocannabinoid system targeted therapeutics market has been analyzed across the following segments:

• • Target Disease Indication
• Cancer
• Genetic Disorders
• Neurological Indications
• Others

 

• Route of Administration
• Oral
• Inhalation

 

• Key Geographies
• North America
• Europe

Asia-Pacific and the Rest of the World

 

The “Endocannabinoid System Targeted Therapeutics Market, 2020-2030" report features the following companies, which we identified to be key players in this domain:

• GW Pharmaceuticals
• Corbus Pharmaceuticals
• Tilray
• Tetra Bio-Pharma
• Botanix Pharmaceuticals
• Kalytera Therapeutics
• Therapix Biosciences
• Echo Pharmaceuticals
• Avicanna
• GB Sciences

 

Table of Contents

 

1.         PREFACE

 

2.         EXECUTIVE SUMMARY

 

3.         INTRODUCTION

 

4.         MARKET LANDSCAPE: ENDOCANNABINOID SYSTEM TARGETED THERAPEUTICS

 

5.         COMPANY PROFILES

 

6.         ACADEMIC GRANTS ANALYSIS

 

7.         PARTNERSHIPS AND COLLABORATIONS

 

8.         MERGERS AND ACQUISITIONS

 

9.         DRUG DEVELOPMENT STRATEGY ANALYSIS

10.        MARKET FORECAST AND OPPORTUNITY ANALYSIS

 

11.        CONCLUDING REMARKS

 

12.        EXECUTIVE INSIGHTS

 

13.        APPENDIX 1: TABULATED DATA

 

14.        APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

 

To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/endocannabinoid-therapeutics/316.html

 

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

[email protected]